Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 1, 2010, Pages 34-42

  Nair, Sunil ^a   Wilding, John P H ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; ANTIDIABETIC AGENT; AVE 2268; BI 10773; DAPAGLIFOZIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; JNJ 28431754; METFORMIN; ORAL ANTIDIABETIC AGENT; PHLORIZIN; PLACEBO; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TA 7284; UNCLASSIFIED DRUG;

ADD ON THERAPY; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GENITAL TRACT INFECTION; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN SENSITIVITY; KIDNEY PROXIMAL TUBULE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRERENAL AZOTEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; UREMIA; URINARY TRACT INFECTION; URINE VOLUME; WEIGHT REDUCTION;

EID: 75149196250     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0473     Document Type: Review

References (62)

1. Kanai Y, Lee WS, You G, Brown D, Hediger MA 1994 The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93:397-404
2. Uldry M, Thorens B 2004 The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch 447:480-489
3. Wood IS, Trayhurn P 2003 Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 89:3-9
4. Wright EM, Turk E 2004 The sodium/glucose cotransport family SLC5. Pflügers Arch 447:510-518
5. Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA 1992 Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol 263:F459-F465
6. Zhou L, Cryan EV, D'Andrea MR, Belkowski S, Conway BR, Demarest KT 2003 Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem 90:339-346
7. Li H, Gu Y, Zhang Y, Lucas MJ, Wang Y 2004 High glucose levels down-regulate glucose transporter expression that correlates with increased oxidative stress in placental trophoblast cells in vitro. J Soc Gynecol Invest 11:75-81
8. Turk E, Martín MG, Wright EM 1994 Structure of the human Na+/glucose cotransporter gene SGLT1. J Biol Chem 269:15204-15209
9. Martín MG, Turk E, Lostao MP, Kerner C, Wright EM 1996 Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat Genet 12:216-220
10. van den Heuvel LP, Assink K, Willemsen M, Monnens L 2002 Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 111:544-547
11. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li Volti S, Neuhaus T, Skovby F, Swift PG, Schaub J, Klaerke D 2003 Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria. J Am Soc Nephrol 14:2873-2882
12. Elsas LJ, Rosenberg LE 1969 Familial renal glycosuria: a genetic reappraisal of hexose transport by kidney and intestine. J Clin Invest 48:1845-1854
13. Elsas LJ, Busse D, Rosenberg LE 1971 Autosomal recessive inheritance of renal glycosuria. Metabolism 20:968-975
14. Oemar BS, Byrd DJ, Brodehl J 1987 Complete absence of tubular glucose reabsorption. A new type of renal glucosuria (type-0). Clin Nephrol 27:156-160
15. Calado J, Sznajer Y, Metzger D, Rita A, Hogan MC, Kattamis A, Scharf M, Tasic V, Greil J, Brinkert F, Kemper MJ, Santer R 2008 Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant 23: 3874-3879
16. Ganong WF 2005 Formation and excretion of urine. Rev Med Physiol 22:699-734
17. Zhai XY, Birn H, Jensen KB, Thomsen JS, Andreasen A, Christensen EI 2003 Digital three-dimensional reconstructionandultrastructure of the mouse proximal tubule. J Am Soc Nephrol 14:611-619
18. Turner RJ, Moran A 1982 Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies. Am J Physiol 242:F406-F414
19. Pajor AM, Hirayama BA, Wright EM 1992 Molecular evidence for two renal Na+/glucose cotransporters. Biochim Biophys Acta 1106:216-220
20. Freitas HS, Anhê GF, Melo KF, Okamoto MM, Oliveira-Souza M, Bordin S, Machado UF 2008 Na+-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1α expression and activity. Endocrinology 149:717-724
21. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J 2005 Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54:3427-3434 22. Kamran M, Peterson RG, Dominguez JH 1997 Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol 8:943-948
22. Dominguez JH, Camp K, Maianu L, Feister H, Garvey WT 1994 Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am J Physiol 266:F283-F290
23. Chin E, Zamah AM, Landau D, Grønbcek H, Flyvbjerg A, LeRoith D, Bondy CA 1997 Changes in facilitative glucose transporter messenger ribonucleic acid levels in the diabetic rat kidney. Endocrinology 138:1267-1275
24. Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, Matsumoto M, Saito A, Tsujihara K, Anai M, Asano T, Kanai Y, Endou H 1999 T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48:1794-1800
25. Bautista R, Manning R, Martinez F, Avila-Casado Mdel C, Soto V, Medina A, Escalante B 2004 Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertension. Am J Physiol Renal Physiol 286:F127-F133
26. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J 2005 Phlorizin: a review. Diabetes Metab Res Rev 21:31-38
27. Defronzo RA, Goldberg M, Agus Z 1975 Effects of phlorizin and insulin on tubular phosphate reabsorption. Evidence for 2 transport pathways. Kidney Int 8:472-472
28. Panayotova-Heiermann M, Loo DD, Wright EM 1995 Kinetics of steady-state currents and charge movements associated with the rat Na+/glucose cotransporter. J Biol Chem 270:27099-27105
29. Tsujihara K, Hongu M, Saito K, Inamasu M, Arakawa K, Oku A, Matsumoto M 1996 Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull (Tokyo) 44:1174-1180
30. Shi ZQ, Rastogi KS, Lekas M, Efendic S, Drucker DJ, Vranic M 1996 Glucagon response to hypoglycemia is improved by insulin-independent restoration of normoglycemia in diabetic rats. Endocrinology 137:3193-3199
31. Starke A, Grundy S, McGarry JD, Unger RH 1985 Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes. Proc Natl Acad Sci USA 82:1544-1546
32. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA 1987 Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79:1510-1515
33. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA 1987 Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80:1037-1044
34. Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L 1991 Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 87:561-570
35. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M 2007 Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 320:323-330
36. Ueta K, Ishihara T, Matsumoto Y, Oku A, Nawano M, Fujita T, Saito A, Arakawa K 2005 Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci 76:2655-2668
37. Washburn WN 2009 Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. J Med Chem 52:1785-1794
38. Ohsumi K, Matsueda H, Hatanaka T, Hirama R, Umemura T, Oonuki A, Ishida N, Kageyama Y, Maezono K, Kondo N 2003 Pyrazole-O-glucosides as novel Na+-glucose cotransporter (SGLT) inhibitors. Bioorg Med Chem Lett 13:2269-2272
39. Dudash Jr J, Zhang X, Zeck RE, Johnson SG, Cox GG, Conway BR, Rybczynski PJ, Demarest KT 2004 Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem Lett 14:5121-5125
40. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M 2008 Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 327:268-276
41. Lansdell MI, Burring DJ, Hepworth D, Strawbridge M, Graham E, Guyot T, Betson MS, Hart JD 2008 Design and synthesis of fluorescent SGLT2 inhibitors. Bioorg Med Chem Lett 18:4944-4947
42. Wancewicz EV, Bernd AS, Meibohm B, Yates CR, Pearce M, Matson J, Booten S, Murray SF, Hung G, Geary RS, Bhanot S, Monia BP 2008 Long-term safety and efficacy of ISIS-388626, an optimized SGLT2 antisense inhibitor, in multiple diabetic and euglycemic species. Diabetes 57(Suppl 1): A96 (Abstract)
43. Bhanot S, Murray SF, Booten SL, Chakravarty K, Zanardi T, Henry S, Watts LM, Wancewicz EV, Siwkowski A, Monia BP, ISIS 388626, an SGLT2 antisense drug, causes robust and sustained glucosuria in multiple species and is safe and well-tolerated. Proc of the 69th Scientific Session of the American Diabetes Association, June 5-9, 2009, New Orleans, LA (Abstract 328-OR)
44. Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN 2008 Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 51:1145-1149
45. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M 2009 Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 85:520-526
46. Komoroski B, Brenner E, Li L 2007 Dapagliflozin (BMS-512148), a selective SGLT2 inhibitor, inhibits glucose resorption and reduces fasting glucose in patients with type 2 diabetes mellitus. Diabetologia 50(Suppl 1):S315 (Abstract 0763)
47. List JF, Woo V, Morales E, Tang W, Fiedorek FT 2009 Sodium-glucose co-transport inhibition with dapagliflozin in type 2 diabetes mellitus. Diabetes Care 32:650-657
48. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT 2009 A pilot study of dapagliflozin in patients with type 2 diabetes on high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32:1656-1662
49. Kler L, Hussey EK, Dobbins RL, O'Connor-Semmes RL, Kapur A, Murray SC, Clark RV, Stotlz RR, Stockman NL, Amin DM, Kipnes MS, O'Driscoll EC, Leong J, Nunez DJR 2007 Clinical studies to assess safety, pharmacokinetics and pharmacodynamics of sergliflozin, a novel inhibitor of glucose reabsorption. Diabetologia 50(Suppl 1):S376 (Abstract 0914)
50. Hussey EK, Clark RV, Amin DM 2007 Early clinical studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus. Diabetes 56:A49 (Abstract)
51. Hussey EK, O'Connor-Semmes RL, Tao W, Poo JL, Dobbins RL, Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate (SGLT2 inhibitor) and metformin when co-administered in type 2 diabetes mellitus patients. Proc of the 69th Scientific Session of the American Diabetes Association, June 5-9, 2009, New Orleans, LA (Abstract 582-P)
52. Kapur AR, Hussey E, Dobbins RL, Tao W, Hompesch M, Nunez DJ, First human dose escalation study with remogliflozin etabonate (RE) in healthy subjects and in subjects with type 2 diabetes mellitus. Proc of the 69th Scientific Session of the American Diabetes Association, June 5-9, 2009, New Orleans, LA (Abstract 509-P)
53. Hoepelman AI, Meiland R, Geerlings SE 2003 Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents 22(Suppl 2): 35-43
54. Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet TJ, Hoepelman AI 2000 Risk factors forsymptomaticurinary tract infection in women with diabetes. Diabetes Care 23:1737-1741
55. Scudamore JA, Tooley PJ, Allcorn RJ 1992 The treatment of acute and chronic vaginal candidosis. Br J Clin Pract 46:260-263
56. Sobel JD 1993 Candidal vulvovaginitis. Clin Obstet Gynecol 36: 153-165
57. Bohannon NJ 1998 Treatment of vulvovaginal candidiasis in patients with diabetes. Diabetes Care 21:451-456
58. Bickel M, Brummerhop H, Frick W, Glombik H, Herling AW, Heuer HO, Plettenburg O, Theis S, Werner U, Kramer W 2008 Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung 58:574-580
59. Whaley J, Hagan D, Taylor J, Xin L, Han SP, Meng W, Ellsworth B, Sher P, McCann P, Wu G, Biller S, Wetterau J, Washburn W 2007 Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 56:A149
60. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM 2008 Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57:1723-1729
61. Liang Y, Arakawa K, Martin T, Du F, Zhi Xu J, Liu Y, Finley M, Minor L, Lenhard J, Demarest K, JNJ-28431754/TA-7284, an SGLT inhibitor, lowers blood glucose and reduces body weight in obese and type 2 diabetic animal models. Proc of the 69th Scientific Session of the American Diabetes Association, June 5-9, 2009, New Orleans, LA (Abstract 534-P)
62. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Mark M, Eickelmann P, In vitro properties and in vivo effect on urinary glucose excretion of BI 10773, a novel selective SGLT2 inhibitor. Proc of the 69th Scientific Session of the American Diabetes Association, June 5-9, 2009, New Orleans, LA (Abstract 521-P)